Diagnostic microbiology and infectious disease最新文献

{"title":"Evaluation of the AllplexTM stx1/2/2a/2d Typing (ASTXT) assay for the diagnosis and typing of Shiga toxin-producing Escherichia coli","authors":"Hyeon Ji Lee ,&nbsp;Hyeon-Joong Kim ,&nbsp;Soon Seong Choi ,&nbsp;Hye Jeong Choo ,&nbsp;Hee Jae Huh ,&nbsp;Eun Jeong Won","doi":"10.1016/j.diagmicrobio.2024.116645","DOIUrl":"10.1016/j.diagmicrobio.2024.116645","url":null,"abstract":"<div><div>This study assessed the performance of the Allplex^TM stx1/2/2a/2d Typing (ASTXT) assay (Seegene) for diagnosis and typing Shiga toxin-producing <em>Escherichia coli.</em> Analytical sensitivity and specificity were evaluated using 18 spiked strains, and cross-reactivity was tested on 114 strains including <em>E. coli</em> without Shiga toxin. Clinical performance was evaluated using the proficiency panels and 76 stool samples. Analytical sensitivity was revealed to 4.14 log₁₀ CFU ml⁻¹ for <em>E. coli</em> strain with <em>stx1</em>, 4.47 log₁₀ CFU ml⁻¹ for strain with <em>stx2,</em> 4.03 log₁₀ CFU ml⁻¹ for strain with <em>stx2a,</em> and 4.02 log₁₀ CFU ml⁻¹ for strain with <em>stx2d,</em> respectively. Imprecisions were within 5 % and cross-reactivity was not observed. The ASTXT assay showed perfect agreement with the proficiency panel results and achieved 100 % positive and negative percent agreement using clinical stool samples. The ASTXT assay demonstrated reliable performance for the rapid detection and typing of Shiga toxin-producing <em>E. coli</em> in human stool samples.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"111 3","pages":"Article 116645"},"PeriodicalIF":2.1,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The diagnostic value of metagenomic next-generation sequencing in suspected pulmonary tuberculosis patients with scarce sputum or negative sputum etiological test results","authors":"Wanfeng Xiong ,&nbsp;Liang Dong ,&nbsp;Ning Zhu ,&nbsp;Daibing Zhou ,&nbsp;Shuanghui Li ,&nbsp;Junzhu Lv ,&nbsp;Mengqi Xu ,&nbsp;Yuhai Zhang ,&nbsp;Shengqing Li","doi":"10.1016/j.diagmicrobio.2024.116633","DOIUrl":"10.1016/j.diagmicrobio.2024.116633","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the diagnostic value between mNGS and conventional tests in suspected pulmonary tuberculosis (PTB) patients with scarce sputum or with negative sputum etiological test results.</div></div><div><h3>Methods</h3><div>We enrolled eligible patients admitted to our department from 2018 to 2021. Their bronchoalveolar lavage fluid (BALF) and lung biopsy tissue samples were sent for mNGS and conventional tests. The diagnostic value of mNGS was compared respectively with that of conventional tests.</div></div><div><h3>Results</h3><div>94 of 226 enrolled patients were diagnosed PTB. The diagnostic concordance rate of mNGS was significantly higher than that of acid-fast staining in all samples (<em>p</em> &lt; 0.001), as well as that of culture in BALF samples (<em>p</em> = 0.011). mNGS in parallel with conventional tests had significantly higher AUC than mNGS alone (<em>p</em> = 0.013).</div></div><div><h3>Conclusions</h3><div>mNGS has higher diagnostic value than some conventional tests. mNGS in parallel with conventional tests is more reliable to accurately diagnose these suspected PTB patients.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"111 3","pages":"Article 116633"},"PeriodicalIF":2.1,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design of immunoassay based biosensor platforms for SARS-CoV-2 detection using highly specific monoclonal antibodies","authors":"Göknur Gizem Dinç ,&nbsp;Ebru Saatçi ,&nbsp;İlkay Göksu Polat ,&nbsp;Fatıma Yücel ,&nbsp;Uygar Halis Tazebay ,&nbsp;Esin Akçael","doi":"10.1016/j.diagmicrobio.2024.116644","DOIUrl":"10.1016/j.diagmicrobio.2024.116644","url":null,"abstract":"<div><div>The global expand of SARS-CoV-2 has highlighted the importance of early and rapid detection to control the spread of a pandemic. In this study, specific and high-affinity monoclonal antibodies (mAbs) were developed against the conserved nucleocapsid protein of the virus among variants. Appropriate antibody pairs were selected to develop a lateral flow immunoassay (LFIA) and an unconventional application of an amperometric biosensor using unmodified screen-printed electrodes and external magnetic bead preparation. In the study, the LFIA we developed detected the SARS-CoV-2 virus at 10⁴ PFU/mL, while the amperometric biosensor enabled sensitive detection of inactivated SARS-CoV-2 with an LOD of 5.5 PFU/mL. After validating the developed systems, it is considered that the mAbs we have obtained will enable the sensitive and selective detection of SARS-CoV-2 in LFIA and amperometric immunosensor platforms for clinical diagnosis.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"111 3","pages":"Article 116644"},"PeriodicalIF":2.1,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The development of therapeutics and vaccines against COVID-19.","authors":"Tianyu Zhao,&nbsp;Zhiwei Wang,&nbsp;Mingjiong Tong,&nbsp;Yingming Fei","doi":"10.1016/j.diagmicrobio.2024.116643","DOIUrl":"10.1016/j.diagmicrobio.2024.116643","url":null,"abstract":"<div><div>Since the COVID-19 pandemic, it has caused a great threat to the global economy and public health, initiatives have been launched to control the spread of the virus. To explore the efficacy of drugs, a large number of clinical trials have been carried out, with the purpose of providing guidelines based on high-quality evidence for clinicians. We mainly discuss therapeutic agents for COVID-19 and explain the mechanism, including antiviral agents, tocilizumab, Janus kinase (JAK) inhibitors, neutralizing antibody therapies and corticosteroids. In addition, the COVID-19 vaccine has been proven to be efficacious in preventing SARS-CoV-2 infection. We systematically analyzed four mainstream vaccine platforms: messenger RNA (mRNA) vaccines, viral vector vaccines, inactivated vaccines and protein subunit vaccines. We evaluated the therapeutic effects of drugs and vaccines through enumerating the most typical clinical trials. However, the emergence of novel variants has further complicated the interpretation of the available clinical data, especially vaccines and antibody therapies. In the post-epidemic era, therapeutic agents are still the first choice for controlling the progression of disease, whereas the protective effect of vaccines against different strains should be assessed comprehensively.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"111 3","pages":"Article 116643"},"PeriodicalIF":2.1,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of Copeptin in viral lower respiratory tract infections in child: A prospective case-control study","authors":"Berker Okay ,&nbsp;Halil Ugur Hatipoglu ,&nbsp;Zeynep Uze Okay ,&nbsp;Cevher Kızılırmak ,&nbsp;Ahsen Guler ,&nbsp;Kâmil Sahin ,&nbsp;Gulsen Akkoc","doi":"10.1016/j.diagmicrobio.2024.116641","DOIUrl":"10.1016/j.diagmicrobio.2024.116641","url":null,"abstract":"<div><h3>Background</h3><div>Lower respiratory tract infection (LRTI) is a leading cause of morbidity and mortality among children globally. Copeptin, released by the pituitary gland, serves as a biomarker for various conditions and, as a neuroendocrine stress hormone, is useful in acute conditions. This study aimed to determine the role of copeptin levels in LRTI in children and whether it can reliably predict pneumonia severity.</div></div><div><h3>Materials and Methods</h3><div>This prospective case-control study was performed between April and October 2023. The study included four groups: (i) patients diagnosed with bronchiolitis (Group 1, n=25), (ii) patients diagnosed with mild to moderate pneumonia (Group 2, n=25), (iii) patients diagnosed with severe pneumonia (Group 3, n=25), and (iv) a control group (Group 4, n=26).</div></div><div><h3>Results</h3><div>Copeptin values differed significantly between the groups (p&lt;0.001 for all comparisons). Copeptin demonstrated a sensitivity of 87.4 % and specificity of 82.2 % for distinguishing between patients with bronchiolitis and pneumonia, using a cut-off value of &gt;0.586 ng/ml. For the identification of patients with severe pneumonia versus those with mild to moderate pneumonia, copeptin exhibited a sensitivity of 97.9 % and specificity of 94.7 % with a cut-off value of &gt;1.215 ng/ml. The copeptin level exhibited a positive correlation with fibrinogen and FAR levels while demonstrating a negative correlation with albumin levels (r=0.354, ^⁎⁎<em>P</em>=0.002; r=0.408, ^⁎⁎⁎<em>P</em>&lt;0.001; and r=−0.334, ^⁎⁎<em>P</em>=0.003, respectively).</div></div><div><h3>Conclusions</h3><div>Copeptin demonstrates potential as a predictor of disease severity in children with pneumonia. It can also serve as a valuable tool to guide physicians in differentiating between bronchiolitis and pneumonia, as well as in diagnosing severe pneumonia.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"111 3","pages":"Article 116641"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Salmonella enterica serovar Enteritidis isolates from South Korea based on whole genome sequences, antibiotic resistance, and virulence assays","authors":"Jihyun Choi ,&nbsp;Jong Hyun Shin ,&nbsp;Ji Young Choi ,&nbsp;Kun Taek Park ,&nbsp;Mi-Ran Seo ,&nbsp;Seung-Hyun Jung ,&nbsp;Yeun-Jun Chung ,&nbsp;Kwan Soo Ko","doi":"10.1016/j.diagmicrobio.2024.116642","DOIUrl":"10.1016/j.diagmicrobio.2024.116642","url":null,"abstract":"<div><div>We compared 15 <em>Salmonella</em> Enteritidis isolates collected in South Korea in 2023: 11 from chickens and 4 from humans. All isolates belonged to ST11, and they were divided into two clusters, rST3888 and rST1425. All four human isolates were colistin-resistant, and <em>mcr-1</em> was identified in three isolates.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"111 3","pages":"Article 116642"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoinformatic predictions and characterization of Schistosoma mansoni peptides as candidates for immunodiagnostic","authors":"Ana Cristina Loiola Ruas ,&nbsp;Ramayana Morais de Medeiros Brito ,&nbsp;Ana Laura Grossi de Oliveira ,&nbsp;Jordânia Costa Pinto ,&nbsp;Tatyane Martins Cirilo ,&nbsp;Agostinho Gonçalves Viana ,&nbsp;João Luís Reis Cunha ,&nbsp;Samuel Alexandre Pimenta Carvalho ,&nbsp;Daniella Castanheira Bartholomeu ,&nbsp;Carlos Graeff-Teixeira ,&nbsp;Silvio Santana Dolabella ,&nbsp;Stefan Michael Geiger ,&nbsp;Deborah Aparecida Negrão-Corrêa ,&nbsp;Lilian Lacerda Bueno ,&nbsp;Ricardo Toshio Fujiwara","doi":"10.1016/j.diagmicrobio.2024.116632","DOIUrl":"10.1016/j.diagmicrobio.2024.116632","url":null,"abstract":"<div><div><em>Schistosoma mansoni</em> represents a significant etiological agent of schistosomiasis, a neglected tropical disease with a global distribution. Although the Kato-Katz technique is an effective diagnostic tool in areas with a high prevalence of the disease, it lacks sensitivity in regions with lower prevalence. The objective of this study was to identify and validate novel immunogenic peptide targets derived from the S. mansoni proteome. The initial set of 14,499 predicted sequences were obtained from the WormBase database, and it was filtered to 8,308 by removing proteins lacking start or stop codons, shorter than 100 amino acids, or with undetermined amino acids. The sequences were then cross-referenced for cross-reactivity and ranked based on B-cell immunogenicity, resulting in the selection of 442 peptides for synthesis and screening. Immunoblotting revealed 22 reactive peptides, with 15 exhibiting specificities for sera from individuals at the initial infection (T0) stage and five reactive to both T0 and post-treatment (30D) sera. Subsequently, 19 peptides were subjected to further validation through molecular weight assessment and synthesized for ELISA testing. The multi-peptide pool demonstrated a reactivity frequency of 54.5 % in infected individuals, which surpassed the reactivity frequencies observed for individual peptides. The six peptides exhibiting the highest reactivity were subsequently analyzed according to infection intensity. The multi-peptide pool exhibited the highest reactivity (65.2 %) in low-intensity cases. ROC curve analysis indicated that Peptide 15 demonstrated the highest sensitivity (78.79 %) and specificity (87.5 %), while the multi-peptide pool exhibited 67.65 % sensitivity and 81.82 % specificity. These findings highlight the potential of peptide-based diagnostics to enhance the detection and control of schistosomiasis.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"111 3","pages":"Article 116632"},"PeriodicalIF":2.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mycobacterium leprae infection with rash misdiagnosed as a flare-up of systemic lupus erythematosus: a case report","authors":"Yihan Zhao ,&nbsp;Shijie Huang ,&nbsp;Tong Wu","doi":"10.1016/j.diagmicrobio.2024.116622","DOIUrl":"10.1016/j.diagmicrobio.2024.116622","url":null,"abstract":"<div><div>Background: Leprosy (Hansen's disease) is a curable, chronic contact infectious disease caused by <em>Mycobacterium leprae</em>. It mainly affects human skin and nerves and can cause progressive and permanent damage to the skin, nerves, limbs, eyes and is of great concern to the medical community.</div><div>Case presentation: A 35-year-old Han Chinese female patient presented to our hospital with 11 years of recurrent erythema and pain in the limbs and face, which was aggravated by fever for 6 days. The patient had an 11-year history of systemic lupus erythematosus (SLE). Initially, lupus was considered to be active and was subsequently treated with methylprednisolone; however, the rash was not controlled. By completing pathohistological examination, immunohistochemistry, and antacid staining, according to the Ridley-Jopling classification of leprosy, confirmed a diagnosis of lepromatous leprosy.</div><div>Conclusions: This report will help increase awareness of leprosy in patients with immune disorders to reduce the rate of misdiagnosis and mistreatment.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"111 3","pages":"Article 116622"},"PeriodicalIF":2.1,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urine and serum-based ELISA using a recombinant protein and synthetic peptide for the diagnosis of tegumentary leishmaniasis","authors":"Camila S. Freitas ,&nbsp;Raquel S.B. Câmara ,&nbsp;Daniela P. Lage ,&nbsp;Danniele L. Vale ,&nbsp;Ana L. Silva ,&nbsp;Breno L. Pimenta ,&nbsp;Fernanda Ludolf ,&nbsp;Nathália C. Galvani ,&nbsp;Marcelo M. de Jesus ,&nbsp;Bárbara P.N. Assis ,&nbsp;Ana T. Chaves ,&nbsp;Grasiele S.V. Tavares ,&nbsp;Unaí Tupinambás ,&nbsp;Miguel A. Chávez-Fumagalli ,&nbsp;Vanessa P.M. Pascoal ,&nbsp;Marcela T.C. Eller ,&nbsp;Manoel O. da Costa Rocha ,&nbsp;Myron Christodoulides ,&nbsp;Ricardo A. Machado-de-Ávila ,&nbsp;Denise U. Gonçalves ,&nbsp;Eduardo A.F. Coelho","doi":"10.1016/j.diagmicrobio.2024.116631","DOIUrl":"10.1016/j.diagmicrobio.2024.116631","url":null,"abstract":"<div><div>The diagnosis of tegumentary leishmaniasis (TL) presents problems by the variable sensitivity and specificity of the tests, and the biological samples used are also invasive. Here, ELISA experiments were performed using paired TL patient urine and serum samples in reaction against the recombinant LiHyS protein, a predicted B cell epitope and parasite antigenic extract (SLA). Two hundred and five paired samples were used, which were provided by TL patients, healthy controls and patients with Chagas disease, leprosy, malaria or HIV-infected. An urine-based ELISA showed sensitivity values of 100%, 92.1%, and 82.5%, when rLiHyS, peptide and SLA were used, respectively; and specificity of 100%, 87.6%, and 79.5%, respectively. A serum-based ELISA showed sensitivity values of 100%, 99.3%, and 81.5%, using rLiHyS, peptide and SLA, respectively, and sensitivity of 100%, 96.5%, and 72.2%, respectively. In both cases, rLiHyS presented the better performance to diagnose TL by using patient serum and urine.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"111 3","pages":"Article 116631"},"PeriodicalIF":2.1,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult severe community-acquired pneumonia with bloodstream infection caused by ψUSA 300: A case report","authors":"Shinichi Morimoto ,&nbsp;Mituhiro Kamada ,&nbsp;Yuka Motomura ,&nbsp;Nobuhiro Kashige ,&nbsp;Motoyasu Miyazaki ,&nbsp;Yoshihiko Nakamura ,&nbsp;Tohru Takata","doi":"10.1016/j.diagmicrobio.2024.116630","DOIUrl":"10.1016/j.diagmicrobio.2024.116630","url":null,"abstract":"<div><div>We report the first case of fatal community-acquired pneumonia with concomitant bloodstream infection caused by the ψUSA300 strain of methicillin-resistant Staphylococcus aureus (MRSA). The isolate was positive for Panton–Valentine leukocidin (PVL) gene, with a unique 12-base pair deletion in the <em>ccrB2</em> gene, differentiating it from the canonical USA300 strain. Despite aggressive therapeutic interventions, the patient developed multiple complications, including septic shock, which ultimately proved fatal. Genetic sequencing confirmed the presence of the ψUSA300 strain.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"111 3","pages":"Article 116630"},"PeriodicalIF":2.1,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142747024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}